Status:
ENROLLING_BY_INVITATION
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Myotonic Dystrophy Type 1 (DM1)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Eligibility Criteria
Inclusion
- Key
- • Completed study drug treatment in parent study VX23-670-001 (NCT06185764)
- Key
Exclusion
- • History of any illness or any clinical condition as pre-specified in the protocol
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
April 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 24 2028
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06926621
Start Date
April 28 2025
End Date
July 24 2028
Last Update
November 14 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Wesley Research Institute
Auchenflower, Australia
2
Neuroscience Clinical Trials Unit, Alfred Brain
Melbourne, Australia
3
Altasciences Montreal
Montreal, Canada
4
Montreal Neurological Institute-Hospital
Montreal, Canada